{"id":"NCT02635724","sponsor":"BioCryst Pharmaceuticals","briefTitle":"Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza","officialTitle":"A Phase 3, Multicenter, Single-arm, Open-label, Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of Intravenous Peramivir in Elderly Subjects With Acute Uncomplicated Influenza Infection and in Subjects With Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2018-04","completion":"2018-09","firstPosted":"2015-12-21","resultsPosted":"2021-03-23","lastUpdate":"2021-03-23"},"enrollment":74,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Peramivir","otherNames":["Rapivab"]}],"arms":[{"label":"Peramivir","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications. All subjects will receive IV peramivir.","primaryOutcome":{"measure":"Safety and Tolerability, as Measured by the Number of Adverse Events.","timeFrame":"14 days","effectByArm":[{"arm":"At Risk (<65 Years)","deltaMin":17,"sd":null},{"arm":"Elderly (65-75 Years)","deltaMin":9,"sd":null},{"arm":"Very Elderly (>75 Years)","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Diarrhoea","Wheezing","Dizziness","Breath sounds abnormal","Rash"]}}